In this research, hydrophobic DESs were successfully prepared using components with hydrophobic and sulfydryl group, which were applied to develop a green and eco-friendly method to extract and detect the cadmium (Cd) in herbal medicine (HM).The basic properties of the DESs were studied, which showed good hydrophobicity, low d. and sufficient absorption capacity.In extraction process, the extraction efficiency (EE) of Cd employing proposed process ranged from 89.12 %∼94.59 % and the maximal enrichment factor (EF) was 46.85.The DES based method demonstrated a good linear response in the range of 1 ∼ 50 μg·L^-1 with a detection limit (LOD) of 0.29 μg L^-1, which was detected by Inductively coupled plasma mass spectrometry (ICP-MS).Addnl., the accuracy of method (as recoveries %) was obtained with the recoveries ranging from 98.38 %∼105.48 %.The extraction process was also compared with microwave digestion (MD) method and showed basically equivalent effect with good propensity to enrichment.The mechanism was explored by DFT calculation to reveal the interaction of extraction process.The greenness of the proposed method was also evaluated using the Green Anal. Procedure Index (GAPI) and Anal. Eco-Scale (AES), which indicated excellent environmental protection.This study successfully prepared novel DESs and established an eco-friendly and effective anal. process integrating adsorption, collection, separation and detection for the detection of heavy metals in HM, and the DESs were contributed to the first three parts as a multifunctional role.The absorption mechanism related to the formation of mol. complexes in quantum chem. perspective, which were attribute to the electrostatic attraction and H⁺ exchange between Cd and adsorbent.This method showed vast potential in heavy metal research involving complex matrixes such as HM and its processed products, and the proposed process provides the way for a greener alternative for Cd extraction rather than conventional polluting processes.

2025-01-01·Journal of Ethnopharmacology

Mechanism of Biqi capsules in the treatment of gout based on network pharmacology and experimental verification

Article

作者: Wu, Yuzheng ; Wang, Yang ; Du, Simiao ; Zhang, Yi ; Wang, Tao ; Cheng, Meifang ; Chen, Qian ; Zhang, Xiangqi ; Wang, Dan ; Li, Ge ; Yan, Siya ; Bu, Ruizhen

ETHNOPHARMACOLOGICAL RELEVANCEGout is a crystal-related arthropathy caused by monosodium urate (MSU) deposition, resulting from purine metabolism disorders and hyperuricemia (HUA). Gout belongs to the traditional medicine category of Bi syndrome. Biqi capsules (BQ) is a traditional Chinese medicine formula used to treat Bi syndrome. The BQ prescription is derived from the ancient prescription of Hua Tuo, a famous physician in the Han Dynasty.AIM OF THE STUDYTo study the effect and mechanism of BQ in treating acute gouty arthritis (AGA) and HUA.MATERIALS AND METHODSAnalyzing BQ's signaling pathways for gout treatment via network pharmacology. The HUA model was induced orally with adenine and potassium oxonate. The rat AGA model was established by MSU injection. In vitro, MH7A and RAW 246.7 cells were treated with LPS and MSU. Serum uric acid, creatinine, and urea nitrogen levels were evaluated. Kidney and ankle joint pathology was observed via HE staining. Inflammatory signaling pathway proteins, epithelial-mesenchymal transition (EMT) pathway proteins, and uric acid metabolism-related proteins were detected by Western blot.RESULTS1780 potential targets for gout treatment were identified, and 1039 target proteins corresponding to BQ's active ingredients were obtained. Pathway enrichment analysis revealed BQ improved gout mainly through inflammatory pathways. Experimental results showed BQ could reduce serum uric acid level and increase uric acid clearance rate by regulating the expression of adenosine deaminase (ADA), and organic anion transporter 1 (OAT1) and glucose transporter 9 (GLUT9) in HUA mice. BQ could improve renal function and injury by inhibiting the NLRP3 pathway in HUA mice' kidneys. Additionally, BQ could alleviate ankle joint swelling and synovial injury, inhibit the TLR4/NLRP3 pathway, and reduce levels of inflammatory factors including interleukin 6 (IL-6), interleukin 1β (IL-1β), and tumor necrosis factor-alpha (TNF-α) in AGA rats. The main component of BQ, brucine, could inhibit the activation of NLRP3/NF-κB pathway induced by MSU and reduce the expression level of inflammatory factors (IL-6, IL-1β, and TNF-α) in macrophages. Brucine could inhibit the activation of the EMT pathway and reduce the expression level of inflammatory factors (IL-6, TNF-α) in human fibroblast-like synoviocytes (MH7A cells) induced by MSU.CONCLUSIONSBQ effectively reduced serum uric acid levels, improved kidney and joint damage, and ameliorated the inflammatory response caused by MSU. Its main component, brucine, effectively improved the inflammatory response and reduced the invasive ability of synoviocytes induced by MSU.

2025-01-01·Journal of Pharmaceutical and Biomedical Analysis

A UPLC-MS/MS coupled with GC-MS method for quantification of twenty-one chemical ingredients from Suxiao Jiuxin pill in multiple tissue of rat and its application to tissue distribution study

Article

作者: Geng, Tong ; He, Jun ; Wang, Yuli ; Wei, Shujie ; Zhu, Yameng ; Zhou, Hong ; Zhou, Shuting ; Wang, Qilong ; Jiang, Yongping ; Liu, Yang ; Shang, Ye

Suxiao Jiuxin pill (SJP) was a commonly-used traditional Chinese medicine for treating cardiovascular diseases. It was composed of the rhizome of Ligusticum chuanxiong Hort. and Borneolum Syntheticum. The distribution of SJP in vivo was still ambiguous. A UPLC-MS/MS coupled with GC-MS method was developed to quantify twenty-one chemical ingredients in multiple tissues from rat after administration of SJP. Protein precipitation and liquid-liquid microextraction were both utilized in sample pretreatment. All analytes were detected under acceptable specificity, linearity (correlation coefficient > 0.992), sensitivity (LLOQ < 12.5 ng/mL), precision (RSD < 14.8 %), accuracy (RE < ±14.6 %), extraction recovery (between 52.8 % and 124.1 %), matrix effect (ranged from 60.5 % and 149.7 %) and stability (RE < ±16.0 %). The established method was successfully applied in the tissue distribution study of SJP in rats. As a result, the distribution characteristics of ten analytes were clearly elucidated, including borneol, isoborneol, ligustilide, senkyunolide A, ferulic acid, senkyunolide I, levistolide A, neocnidilide, senkyunolide H and angelicide. The information provided by this research was greatly meaningful for the active chemical ingredient exploration and clinical application of SJP.

115

项与天津中医药大学相关的新闻（医药）

2024-10-29

·PRNewswire

The 21st World Congress of Chinese Medicine - Seminar on the Integration of Industry and Education in Cardiovascular and Cerebrovascular Diseases Kicks off in Paris

PAIRS, Oct. 28, 2024 /PRNewswire/ -- On October 25, 2024, the 21st World Congress of Chinese Medicine (WCCM) commenced at the United Nations Educational, Scientific and Cultural Organization (UNESCO) Headquarters in Paris, France. Continue Reading (Group Photo at the Seminar on the Integration of Industry and Education in Cardiovascular and Cerebrovascular Diseases) A key highlight of the WCCM was the Seminar on the Integration of Industry and Education in Cardiovascular and Cerebrovascular Diseases on October 26. Hosted by the Industry-Education Integration Promotion Committee of the World Federation of Chinese Medicine Societies (WFCMS) and organized by Jimon Group, the seminar highlighted the latest research achievements and clinical applications of Chinese medicine in cardiovascular diseases. The event aimed to explore the significant value of Chinese medicine in the prevention and treatment of cardiovascular and cerebrovascular diseases, promote in-depth integration of traditional Chinese and modern medicine, and enhance benefits for patients worldwide. Ramon Maria Calduch, Chairman of the Supervisory Board of the WFCMS; Zhang Boli, Vice President of the WFCMS, Senior Researcher at the Chinese Academy of Engineering, and a leading practitioner in Chinese medicine; and Niu Liwei, Vice President of the WFCMS Industry-Education Integration Promotion Committee and Chairman of Jimon Group were among the eminent attendees. Other celebrated participants included Liu Xiaohan, Secretary of the Hebei Pharmaceutical Industry Association, and Wang Yi, Secretary of the Party Committee of the Institute of Chinese Medicine at Tianjin University of Traditional Chinese Medicine. During the launch of the Chinese Medicine for Global Health Industry Expansion Plan, the Jimon Group Chairman, Mr. Niu, elaborated on the landmark initiative. He explained that Jimon Group intends to further the international expansion of Chinese medicine, and establish a Chinese Medicine Industry-Education Integration Expansion Center in Paris, with the goal of contributing its expertise and resources to the creation of a global health community. The WCCM also featured a signing ceremony to formalize collaborations between Jimon Group and several entities, including the WFCMS Industry-Education Integration Promotion Committee, the Association des Ingénieurs Chinois en France, the International Chinese Medicine and Healthcare General Association of the U.S.A., and Canada-based United Wings Enterprise Inc. Through these partnerships, Jimon Group seeks to expand its market reach while enhancing the adaptability and competitiveness of its products by utilizing local resources. The ultimate goal is to broaden the reach and improve the recognition and implementation of Chinese medicine in global health practices. During the roundtable dialogue session, leading practitioners and researchers engaged in a lively discussion on the progress and future of Chinese medicine in treating cardiovascular and cerebrovascular diseases. Eminent leaders in the field from Germany, Australia, and Canada exchanged ideas on the global expansion of Chinese medicine, focusing on its cultural inheritance, innovations, and international collaboration. Jimon Group's involvement in the WCCM not only showcased its robust capabilities and remarkable achievements in the realm of Chinese medicine, but also highlighted its role in advancing the practice on a global scale. Looking forward, the company remains committed to its mission of "Inheriting the culture of Chinese medicine and leading the future of health," with plans to increase its investment in scientific research. In doing so, Jimon Group aims to champion both the cultural heritage and the latest innovations in Chinese medicine, striving to substantially impact the global prevention and treatment of cardiovascular and cerebrovascular diseases. SOURCE Jimon Group WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

2024-09-15

·生物制品圈

新发现！复旦大学/天津中医药大学合作发文：诱导癌细胞转化为脂肪细胞的背后机制

【导读】癌症是一种涉及复杂分子网络的全身性异质性疾病。肿瘤的形成涉及上皮-间充质转化(EMT)， EMT促进肿瘤细胞的转移和可塑性。最近的实验表明，癌细胞可以通过药物的联合作用转化为脂肪细胞。然而，从分子网络的角度来看，这些药物的作用机制仍然难以捉摸。 9月11日，复旦大学与天津中医药大学研究人员合作共同在期刊《Advanced Science》上发表了研究论文，题为“Energy Landscape Reveals the Underlying Mechanism of Cancer-Adipose Conversion in Gene Network Models”，本研究采用系统生物学方法，结合数学建模和分子实验，基于其底层的分子调节网络，识别出四种吸引子，分别对应于上皮细胞(E)、间质细胞(M)、脂肪细胞(A)和部分/中间上皮-间质转化(P)细胞状态的CAC景观。景观和过渡路径结果表明，中间状态在癌症向脂肪转化过程中起着关键作用。通过景观控制方法，识别出两种新的药物组合治疗策略，以促进CAC。这些预测在不同的细胞系中通过分子实验得到验证。计算和实验相结合的方法为探索癌症网络中细胞命运转换的分子机制提供了有力工具。本研究结果揭示了控制CAC的中间细胞状态的潜在机制，并识别出新的潜在药物组合以诱导癌症脂肪生成。 https://onlinelibrary-wiley-com.libproxy1.nus.edu.sg/doi/10.1002/advs.202404854 背景知识 01 癌症的形成是一个由多重过渡状态所控制的复杂过程，这些过渡状态受底层基因调控网络的调控。肿瘤细胞会经历上皮-间质转化（EMT）和间质-上皮转化（MET），以实现可塑性和转移。EMT过程增强了癌细胞的可塑性，并被认为有助于癌症转移。有人提出，经历EMT和/或MET的细胞进入一种高度可塑的状态，这可能为治疗干预提供了关键窗口。例如，最近的研究表明，通过特定的治疗方法，癌细胞可以转化为脂肪细胞。然而，目前尚不清楚驱动这种癌症-脂肪转化（CAC）的机制。这促使研究人员探索控制CAC中细胞命运决定的分子调控网络。动态建模方法为分析生物网络的功能和行为提供了有效的工具，例如用于研究EMT和癌症网络。同时，由于细胞内和作用于细胞的外部波动的存在，需要考虑细胞命运决定的随机描述。基于经典沃丁顿表观遗传景观隐喻的能量景观理论已被开发用于研究基因调控网络的随机动力学，例如在发育和癌变过程中发生的情况。从景观视角来看，细胞类型可以由景观上的吸引力盆地来表征，这反映了不同细胞类型的出现概率。具有较低势能（或较高概率）的状态代表吸引子或具有生物学功能的状态，构成吸引力盆地或稳定状态。从这个角度来看，如肿瘤发生或分化等生物学过程可以被理解为从一个吸引子状态到另一个状态的基因表达状态空间中基因调控网络的过渡。此外，可以通过最小作用路径方法从景观中量化吸引子或细胞类型的动态转换路径。这些方法可以揭示转换过程中基因激活或失活的顺序，并作为探索细胞从癌变到成为脂肪细胞转换机制的强大概念/理论工具。分子实验验证了联合用药诱导癌细胞成脂的有效性 02 研究人员选取肝癌(Hep3B、Huh-7)、乳腺癌(MDA-MB-231)和结直肠癌(SW480、SW620)侵袭性细胞株建立ZEB1过表达模型进行实验验证。过表达ZEB1后，细胞的体积和增殖率增加。罗格列酮处理24 h后细胞形态趋于圆形。在Hep3B和MDA-MB-231细胞系中克隆形成实验表明，ZEB1过表达促进细胞增殖，罗格列酮处理可抑制其增殖。为了评估脂滴的积聚，研究人员使用油红染色，观察到与ZEB1单独过表达相比，ZEB1过表达和罗格列酮联合处理的脂滴形成增强。罗格列酮联合过表达ZEB1促进肿瘤细胞向脂肪细胞转化研究人员通过蛋白质免疫印迹实验和qRT-PCR分析了脂质代谢和脂肪生成标记物，包括PPARγ， C/EBPα和Fabp4，发现ZEB1和罗格列酮一起过表达显著促进脂质代谢和脂肪生成。在肝癌(Huh-7)和结直肠癌(SW480, SW620)细胞中观察到类似的结果。BODIPY脂质染色进一步证实了联合治疗后脂滴的增加。此外，通过划痕实验和迁移实验来探讨对肿瘤细胞侵袭性的影响。结果表明，ZEB1的过表达增强了肿瘤的侵袭性，而随后的罗格列酮治疗显著降低了这种作用，影响了肿瘤细胞的迁移。值得注意的是，研究人员使用的乳腺癌细胞株(MDA-MB-231)是P53突变型细胞株，而肝癌细胞株(Hep3B)是P53野生型细胞株。因此，研究人员的联合药物对有和无P53突变的两种细胞系都有效，这也得到了建模结果的支持。通过模型预测，研究人员进一步检验了另一种药物组合的影响，即添加罗格列酮和MDM2过表达。值得注意的是，在Hep3B细胞系中，MDM2蛋白水平随着ZEB1的过表达而增加，可能是由于ZEB1通过miR-145间接激活MDM2。MDM2过表达联合罗格列酮促进CAC的作用进一步得到实验证实。BODIPY的免疫荧光阳性染色和BODIPY的流式细胞术检测显示，联合用药后，肿瘤细胞脂滴增加。同时，迁移实验显示过表达MDM2后肿瘤侵袭能力增强，加入罗格列酮后肿瘤细胞迁移能力明显降低。进一步分析显示，联合用药后SGBS细胞成脂分化(第7天)与我们诱导的细胞相似(MDA-MB-231细胞的相关系数从0.69增加到0.72,Hep3B细胞的相关系数从0.52增加到0.74)，说明联合用药后的癌细胞被诱导成更具有成熟脂肪细胞的特征。综上所述，RNA-seq结果进一步支持研究人员预测的联合药物可以有效诱导癌细胞向脂肪细胞转化。研究小结 03 综上所述，本研究工作通过基因网络模型提供了对癌症-脂肪转化的全面理解。景观和过渡路径为理解癌症网络中细胞命运决定的潜在机制提供了一个框架，并有助于设计原则，以优化癌症治疗的联合药物策略。【参考资料】https://onlinelibrary-wiley-com.libproxy1.nus.edu.sg/doi/10.1002/advs.202404854 识别微信二维码，添加生物制品圈小编，符合条件者即可加入生物制品微信群！请注明：姓名+研究方向！版权声明本公众号所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系(cbplib@163.com)，我们将立即进行删除处理。所有文章仅代表作者观点，不代表本站立场。

基因疗法

2024-09-15

·今日头条

新发现！复旦大学/天津中医药大学合作发文：诱导癌细胞转化为脂肪细胞的背后机制

【导读】癌症是一种涉及复杂分子网络的全身性异质性疾病。肿瘤的形成涉及上皮-间充质转化(EMT)， EMT促进肿瘤细胞的转移和可塑性。最近的实验表明，癌细胞可以通过药物的联合作用转化为脂肪细胞。然而，从分子网络的角度来看，这些药物的作用机制仍然难以捉摸。 9月11日，复旦大学与天津中医药大学研究人员合作共同在期刊《Advanced Science》上发表了研究论文，题为“Energy Landscape Reveals the Underlying Mechanism of Cancer-Adipose Conversion in Gene Network Models”，本研究采用系统生物学方法，结合数学建模和分子实验，基于其底层的分子调节网络，识别出四种吸引子，分别对应于上皮细胞(E)、间质细胞(M)、脂肪细胞(A)和部分/中间上皮-间质转化(P)细胞状态的CAC景观。景观和过渡路径结果表明，中间状态在癌症向脂肪转化过程中起着关键作用。通过景观控制方法，识别出两种新的药物组合治疗策略，以促进CAC。这些预测在不同的细胞系中通过分子实验得到验证。计算和实验相结合的方法为探索癌症网络中细胞命运转换的分子机制提供了有力工具。本研究结果揭示了控制CAC的中间细胞状态的潜在机制，并识别出新的潜在药物组合以诱导癌症脂肪生成。 https://onlinelibrary-wiley-com.libproxy1.nus.edu.sg/doi/10.1002/advs.202404854 背景知识 01 癌症的形成是一个由多重过渡状态所控制的复杂过程，这些过渡状态受底层基因调控网络的调控。肿瘤细胞会经历上皮-间质转化（EMT）和间质-上皮转化（MET），以实现可塑性和转移。EMT过程增强了癌细胞的可塑性，并被认为有助于癌症转移。有人提出，经历EMT和/或MET的细胞进入一种高度可塑的状态，这可能为治疗干预提供了关键窗口。例如，最近的研究表明，通过特定的治疗方法，癌细胞可以转化为脂肪细胞。然而，目前尚不清楚驱动这种癌症-脂肪转化（CAC）的机制。这促使研究人员探索控制CAC中细胞命运决定的分子调控网络。动态建模方法为分析生物网络的功能和行为提供了有效的工具，例如用于研究EMT和癌症网络。同时，由于细胞内和作用于细胞的外部波动的存在，需要考虑细胞命运决定的随机描述。基于经典沃丁顿表观遗传景观隐喻的能量景观理论已被开发用于研究基因调控网络的随机动力学，例如在发育和癌变过程中发生的情况。从景观视角来看，细胞类型可以由景观上的吸引力盆地来表征，这反映了不同细胞类型的出现概率。具有较低势能（或较高概率）的状态代表吸引子或具有生物学功能的状态，构成吸引力盆地或稳定状态。从这个角度来看，如肿瘤发生或分化等生物学过程可以被理解为从一个吸引子状态到另一个状态的基因表达状态空间中基因调控网络的过渡。此外，可以通过最小作用路径方法从景观中量化吸引子或细胞类型的动态转换路径。这些方法可以揭示转换过程中基因激活或失活的顺序，并作为探索细胞从癌变到成为脂肪细胞转换机制的强大概念/理论工具。分子实验验证了联合用药诱导癌细胞成脂的有效性 02 研究人员选取肝癌(Hep3B、Huh-7)、乳腺癌(MDA-MB-231)和结直肠癌(SW480、SW620)侵袭性细胞株建立ZEB1过表达模型进行实验验证。过表达ZEB1后，细胞的体积和增殖率增加。罗格列酮处理24 h后细胞形态趋于圆形。在Hep3B和MDA-MB-231细胞系中克隆形成实验表明，ZEB1过表达促进细胞增殖，罗格列酮处理可抑制其增殖。为了评估脂滴的积聚，研究人员使用油红染色，观察到与ZEB1单独过表达相比，ZEB1过表达和罗格列酮联合处理的脂滴形成增强。罗格列酮联合过表达ZEB1促进肿瘤细胞向脂肪细胞转化研究人员通过蛋白质免疫印迹实验和qRT-PCR分析了脂质代谢和脂肪生成标记物，包括PPARγ， C/EBPα和Fabp4，发现ZEB1和罗格列酮一起过表达显著促进脂质代谢和脂肪生成。在肝癌(Huh-7)和结直肠癌(SW480, SW620)细胞中观察到类似的结果。BODIPY脂质染色进一步证实了联合治疗后脂滴的增加。此外，通过划痕实验和迁移实验来探讨对肿瘤细胞侵袭性的影响。结果表明，ZEB1的过表达增强了肿瘤的侵袭性，而随后的罗格列酮治疗显著降低了这种作用，影响了肿瘤细胞的迁移。值得注意的是，研究人员使用的乳腺癌细胞株(MDA-MB-231)是P53突变型细胞株，而肝癌细胞株(Hep3B)是P53野生型细胞株。因此，研究人员的联合药物对有和无P53突变的两种细胞系都有效，这也得到了建模结果的支持。通过模型预测，研究人员进一步检验了另一种药物组合的影响，即添加罗格列酮和MDM2过表达。值得注意的是，在Hep3B细胞系中，MDM2蛋白水平随着ZEB1的过表达而增加，可能是由于ZEB1通过miR-145间接激活MDM2。MDM2过表达联合罗格列酮促进CAC的作用进一步得到实验证实。BODIPY的免疫荧光阳性染色和BODIPY的流式细胞术检测显示，联合用药后，肿瘤细胞脂滴增加。同时，迁移实验显示过表达MDM2后肿瘤侵袭能力增强，加入罗格列酮后肿瘤细胞迁移能力明显降低。进一步分析显示，联合用药后SGBS细胞成脂分化(第7天)与我们诱导的细胞相似(MDA-MB-231细胞的相关系数从0.69增加到0.72,Hep3B细胞的相关系数从0.52增加到0.74)，说明联合用药后的癌细胞被诱导成更具有成熟脂肪细胞的特征。综上所述，RNA-seq结果进一步支持研究人员预测的联合药物可以有效诱导癌细胞向脂肪细胞转化。研究小结 03 综上所述，本研究工作通过基因网络模型提供了对癌症-脂肪转化的全面理解。景观和过渡路径为理解癌症网络中细胞命运决定的潜在机制提供了一个框架，并有助于设计原则，以优化癌症治疗的联合药物策略。【参考资料】 https://onlinelibrary-wiley-com.libproxy1.nus.edu.sg/doi/10.1002/advs.202404854 【关于投稿】转化医学网（360zhyx.com）是转化医学核心门户，旨在推动基础研究、临床诊疗和产业的发展，核心内容涵盖组学、检验、免疫、肿瘤、心血管、糖尿病等。如您有最新的研究内容发表，欢迎联系我们进行免费报道（公众号菜单栏-在线客服联系），我们的理念：内容创造价值，转化铸就未来！转化医学网（360zhyx.com）发布的文章旨在介绍前沿医学研究进展，不能作为治疗方案使用；如需获得健康指导，请至正规医院就诊。热门推荐活动点击免费报名 🕓 北京｜09月20日-21日 ▶ 第五届单细胞技术应用研讨会暨空间组学前沿研讨会 🕓 上海｜11月15日-16日 ▶ 2024第一届中国类器官转化医学大会点击对应文字查看详情

基因疗法

100 项与天津中医药大学相关的药物交易

登录后查看更多信息

100 项与天津中医药大学相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2024年11月17日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

药物发现

临床2期

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

加参片	慢性心力衰竭更多	临床2期
丹知青娥片	绝经期综合征更多	临床2期
三叶片	2型糖尿病更多	临床2期
CN118236500 ( PD-1 )	肿瘤更多	药物发现
肝清颗粒	非酒精性脂肪性肝炎更多	无进展